Skip to main content

Table 3 Geometric mean titer (GMT) and the geometric mean increase (GMI) in the various groups

From: Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants: randomized, observer-masked, single-center clinical study

Dosage

Age

Baseline

21 days after injection

42 days after injection

 

GMT (95% CI)

GMT (95% CI)

GMI (95% CI)

GMT (95% CI)

GMI (95% CI)

15 μg

6-12 m

7.58

16.63

2.19

145.88

19.25

 

(4.34 ~ 13.24)b

(8.11 ~ 34.07)b

(1.30 ~ 3.69)b

(80.39 ~ 264.73)a

(12.32 ~ 30.08)a

 

13-24 m

13.75

63.90

4.65

255.56

18.59

 

(9.03 ~ 20.94)

(37.46 ~ 108.97)a

(3.22 ~ 6.70)a

(170.61 ~ 382.91)a

(11.59 ~ 29.81)a

 

25-35 m

10.37

65.45

6.31

226.26

21.82

 

(6.50 ~ 16.55)

(40.06 ~ 106.95)a

(4.14 ~ 9.62)a

(151.81 ~ 337.21)a

(13.80 ~ 34.48)a

 

Total

11.05

51.57

4.67

221.11

20.00

 

(8.42 ~ 14.51)

(37.07 ~ 71.76)a

(3.63 ~ 6.00)a

(172.15 ~ 283.99)a

(15.19 ~ 26.34)a

7.5 μg

6-12 m

22.32

66.67

2.99

276.57

12.39

 

(9.97 ~ 49.91)

(28.58 ~ 155.49)a

(1.85 ~ 4.81)a

(166.88 ~ 458.35)a

(7.16 ~ 21.44)a

 

13-24 m

7.63

25.34

3.32

116.04

15.21

 

(5.67 ~ 10.27)

(15.15 ~ 42.39)a

(2.24 ~ 4.93)a

(75.11 ~ 179.31)a

(10.57 ~ 21.89)a

 

25-35 m

10.70

43.53

4.07

180.09

16.83

 

(6.87 ~ 16.65)

(28.89 ~ 65.58)a

(2.85 ~ 5.80)a

(124.11 ~ 261.33)a

(11.20 ~ 25.30)a

 

Total

10.71

37.86

3.54

163.34

15.25

 

(8.22 ~ 13.95)

(27.83 ~ 51.50)a

(2.82 ~ 4.44)a

(127.06 ~ 209.94)a

(12.03 ~ 19.33)a

SI

6-12 m

9.33

8.71

0.93

14.14

1.52

 

(3.62 ~ 24.08)

(3.77 ~ 20.09)

(0.80 ~ 1.09)

(4.70 ~ 42.60)

(0.69 ~ 3.31)

 

13-24 m

7.87

8.52

1.08

12.05

1.53

 

(4.68 ~ 13.22)

(5.51 ~ 13.18)

(0.83 ~ 1.41)

(7.67 ~ 18.94)

(1.10 ~ 2.13)

 

25-35 m

8.71

8.01

0.92

14.74

1.69

 

(5.30 ~ 14.29)

(5.19 ~ 12.37)

(0.81 ~ 1.04)

(8.57 ~ 25.35)

(1.19 ~ 2.41)

 

Total

8.43

8.34

0.99

13.44

1.59

 

(6.14 ~ 11.58)

(6.35 ~ 10.95)

(0.87 ~ 1.12)

(9.74 ~ 18.54)

(1.28 ~ 1.99)

  1. aP < 0.05 compared with the SI group.
  2. bP < 0.05 compared with the 7.5 dose group.